Trifecta Capital Advisors LLC Takes $338,000 Position in 10x Genomics $TXG

Trifecta Capital Advisors LLC bought a new position in shares of 10x Genomics (NASDAQ:TXG) in the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 29,200 shares of the company’s stock, valued at approximately $338,000.

Several other institutional investors have also recently made changes to their positions in TXG. GAMMA Investing LLC grew its position in shares of 10x Genomics by 81.8% during the first quarter. GAMMA Investing LLC now owns 3,586 shares of the company’s stock worth $31,000 after purchasing an additional 1,614 shares in the last quarter. Signaturefd LLC grew its position in shares of 10x Genomics by 134.3% during the first quarter. Signaturefd LLC now owns 4,203 shares of the company’s stock worth $37,000 after purchasing an additional 2,409 shares in the last quarter. Whittier Trust Co. purchased a new stake in shares of 10x Genomics during the first quarter worth about $41,000. PNC Financial Services Group Inc. grew its position in shares of 10x Genomics by 153.6% during the first quarter. PNC Financial Services Group Inc. now owns 5,150 shares of the company’s stock worth $45,000 after purchasing an additional 3,119 shares in the last quarter. Finally, US Bancorp DE grew its position in shares of 10x Genomics by 314.5% during the first quarter. US Bancorp DE now owns 5,973 shares of the company’s stock worth $52,000 after purchasing an additional 4,532 shares in the last quarter. Hedge funds and other institutional investors own 84.68% of the company’s stock.

Insider Transactions at 10x Genomics

In other news, CEO Serge Saxonov sold 9,348 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $128,908.92. Following the completion of the transaction, the chief executive officer owned 945,892 shares in the company, valued at approximately $13,043,850.68. The trade was a 0.98% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, insider Benjamin J. Hindson sold 7,486 shares of 10x Genomics stock in a transaction that occurred on Friday, August 22nd. The stock was sold at an average price of $13.79, for a total value of $103,231.94. Following the completion of the transaction, the insider owned 440,888 shares of the company’s stock, valued at approximately $6,079,845.52. This trade represents a 1.67% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 39,149 shares of company stock worth $539,865. 9.39% of the stock is currently owned by company insiders.

10x Genomics Stock Performance

Shares of 10x Genomics stock opened at $12.07 on Thursday. The stock has a market cap of $1.50 billion, a price-to-earnings ratio of -17.24 and a beta of 2.05. The stock has a 50 day moving average price of $13.05 and a 200-day moving average price of $11.03. 10x Genomics has a one year low of $6.78 and a one year high of $20.83.

10x Genomics (NASDAQ:TXG) last announced its earnings results on Thursday, August 7th. The company reported $0.28 EPS for the quarter, topping analysts’ consensus estimates of ($0.35) by $0.63. The firm had revenue of $172.91 million during the quarter, compared to analysts’ expectations of $139.36 million. 10x Genomics had a negative return on equity of 12.88% and a negative net margin of 13.13%.The company’s quarterly revenue was up 12.9% on a year-over-year basis. During the same quarter in the previous year, the business earned ($0.32) EPS. 10x Genomics has set its Q3 2025 guidance at EPS. Sell-side analysts predict that 10x Genomics will post -1.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Several analysts recently issued reports on TXG shares. Piper Sandler initiated coverage on 10x Genomics in a research report on Thursday, September 11th. They set a “neutral” rating and a $15.00 target price for the company. Canaccord Genuity Group set a $16.00 price objective on 10x Genomics in a research note on Monday, August 11th. Zacks Research downgraded 10x Genomics from a “strong-buy” rating to a “hold” rating in a research note on Friday, September 5th. UBS Group lifted their price objective on 10x Genomics from $12.00 to $13.00 and gave the stock a “neutral” rating in a research note on Friday, August 8th. Finally, Deutsche Bank Aktiengesellschaft set a $14.00 price objective on 10x Genomics and gave the stock a “hold” rating in a research note on Friday, August 8th. Six equities research analysts have rated the stock with a Buy rating, eight have given a Hold rating and two have issued a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $13.65.

10x Genomics Profile

10x Genomics, Inc, a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products.